We are live on ! Find out more
PHXM

PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM

Delisted

PHXM was delisted on the 8th of March, 2024.

Back to rankings

4 hedge funds and large institutions have $12M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more capital invested

Capital invested by funds: $7.66M → $12M (+$4.34M)

33% more funds holding

Funds holding: 3 → 4 (+1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$780

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$35.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$6.12M – – –
NMC
2
NEA Management Company
Maryland
$5.77M – – –
Millennium Management
3
Millennium Management
New York
$106K -$35.2K -451 -29%
Morgan Stanley
4
Morgan Stanley
New York
$1K +$780 +10 New

PHXM Hedge Fund Activity: Q4 2020 in Review

4 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q4 2020, worth a combined $12M — up 57% from $7.66M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PHXM positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $780. The largest seller was Millennium Management, cutting an estimated $35.2K.

  • 4 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q4 2020, up from 3 in Q3 2020.
  • Funds reported $12M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q4 2020, up 57% quarter-over-quarter.
  • 1 fund opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q4 2020 and 0 closed out, a net change of +1 holder.
  • The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q4 2020 was Morgan Stanley, an estimated $780 added.
  • The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q4 2020 was Millennium Management, an estimated $35.2K sold.

Based on aggregated 13F filings for Q4 2020.